• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Robert Rifkin on Lack of Education Surrounding Biosimilars

Article

Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.

Despite their growing prevalence, there is still a lack of biosimilar education amongst stakeholders, said Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.

TranscriptWhat are the biggest barriers facing biosimilars in oncology?

Biosimilars are interesting because of the multiplicity of stakeholders and the about of education you need to do. We found that even with these being out there for a while, and several being approved, there’s still a dramatic lack of education amongst the stakeholders. There are a number of barriers to adoption, whether it’s educating the providers, educating the patients, educating the payers. And then all of the market dynamics.

I think the barriers are falling as we get more and more molecules out there, but there’s still a huge amount of education that needs to be done for all the stakeholders.

Related Videos
Douglas Flora, MD, FACCC
Bridgette J. Picou, LVN, ACLPN, The Well Project
Priscilla Tsondai, MD, MPH, IAS/CIPHER
Mia Moore, PhD, Fred Hutch Cancer Center
Steven Daniel Daveluy, MD, FAAD
Shawn Kwatra, MD, FAAD
Elizabeth Jones, MD, FAAD.
Brittany Craiglow, MD, FAAD
Lawrence F Eichenfield, MD, FAAD.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.